Cargando…
Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease
BACKGROUND: Subretinal fibrosis (SRF) is a vision-threatening complication of Vogt-Koyanagi-Harada disease (VKH). It has long been recognized as a sequela of chronic inflammation. The developmental process of SRF, however, has not been described. The purpose of this study is to provide longitudinal...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769357/ https://www.ncbi.nlm.nih.gov/pubmed/29334924 http://dx.doi.org/10.1186/s12886-018-0670-0 |
_version_ | 1783292884781367296 |
---|---|
author | Zhao, Chan Dong, Fangtian Gao, Fei Liu, Xinshu Pei, Minghang Jia, Shanshan Zhang, Meifen |
author_facet | Zhao, Chan Dong, Fangtian Gao, Fei Liu, Xinshu Pei, Minghang Jia, Shanshan Zhang, Meifen |
author_sort | Zhao, Chan |
collection | PubMed |
description | BACKGROUND: Subretinal fibrosis (SRF) is a vision-threatening complication of Vogt-Koyanagi-Harada disease (VKH). It has long been recognized as a sequela of chronic inflammation. The developmental process of SRF, however, has not been described. The purpose of this study is to provide longitudinal observations of SRF in VKH. METHODS: Retrospective chart review of 10 VKH patients referred to our group between January 2008 and September 2015 at acute uveitic stage with SRF at presentation or who developed SRF during follow up. RESULTS: Ten patients (6 males and 4 females) with a median age of 39.0 (range, 23 to 58) years old were included. The median disease duration at presentation and median duration of follow up were 25.5 (range 5 to 60) days and 32.5 (range 13 to 61) months respectively. At presentation, all patients except one had been inappropriately treated with glucocorticosteroid (insufficiently dosed or tapered too fast) for longer than 2 weeks. Despite large dose oral glucocorticosteroid (1 mg/kg/d prednisone or equivalent) with slow tapering in combination with at least one immunomodulatory agent (cyclosporin A, cyclophosphamide or azathioprine) after presentation, all patients developed bilateral SRF within the first 4 months of disease course and 7 patients within the first 2 months. In 8 patients, shape-change/migration and progressive proliferation/pigmentation of SRF was observed over a period of several months after its formation, and then became quiescent but may further underwent depigmentation or pigmentation. SRF involved macula in 12 eyes (7 patients) and caused treatment resistant macular detachment and severe visual impairment in 6 eyes (4 patients). At the last visit, eyes with macular involvement were more common to had worse final best corrected visual acuity (≤20/50) than those without (9/12 vs. 0/8, p = 0.001). CONCLUSIONS: SRF usually develop early in the disease course in VKH patients who are not adequately controlled; it usually undergoes a highly dynamic process within the subretinal space and may involve the macula and resulted in poor final visual outcome. |
format | Online Article Text |
id | pubmed-5769357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57693572018-01-25 Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease Zhao, Chan Dong, Fangtian Gao, Fei Liu, Xinshu Pei, Minghang Jia, Shanshan Zhang, Meifen BMC Ophthalmol Research Article BACKGROUND: Subretinal fibrosis (SRF) is a vision-threatening complication of Vogt-Koyanagi-Harada disease (VKH). It has long been recognized as a sequela of chronic inflammation. The developmental process of SRF, however, has not been described. The purpose of this study is to provide longitudinal observations of SRF in VKH. METHODS: Retrospective chart review of 10 VKH patients referred to our group between January 2008 and September 2015 at acute uveitic stage with SRF at presentation or who developed SRF during follow up. RESULTS: Ten patients (6 males and 4 females) with a median age of 39.0 (range, 23 to 58) years old were included. The median disease duration at presentation and median duration of follow up were 25.5 (range 5 to 60) days and 32.5 (range 13 to 61) months respectively. At presentation, all patients except one had been inappropriately treated with glucocorticosteroid (insufficiently dosed or tapered too fast) for longer than 2 weeks. Despite large dose oral glucocorticosteroid (1 mg/kg/d prednisone or equivalent) with slow tapering in combination with at least one immunomodulatory agent (cyclosporin A, cyclophosphamide or azathioprine) after presentation, all patients developed bilateral SRF within the first 4 months of disease course and 7 patients within the first 2 months. In 8 patients, shape-change/migration and progressive proliferation/pigmentation of SRF was observed over a period of several months after its formation, and then became quiescent but may further underwent depigmentation or pigmentation. SRF involved macula in 12 eyes (7 patients) and caused treatment resistant macular detachment and severe visual impairment in 6 eyes (4 patients). At the last visit, eyes with macular involvement were more common to had worse final best corrected visual acuity (≤20/50) than those without (9/12 vs. 0/8, p = 0.001). CONCLUSIONS: SRF usually develop early in the disease course in VKH patients who are not adequately controlled; it usually undergoes a highly dynamic process within the subretinal space and may involve the macula and resulted in poor final visual outcome. BioMed Central 2018-01-15 /pmc/articles/PMC5769357/ /pubmed/29334924 http://dx.doi.org/10.1186/s12886-018-0670-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Zhao, Chan Dong, Fangtian Gao, Fei Liu, Xinshu Pei, Minghang Jia, Shanshan Zhang, Meifen Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease |
title | Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease |
title_full | Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease |
title_fullStr | Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease |
title_full_unstemmed | Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease |
title_short | Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease |
title_sort | longitudinal observation of subretinal fibrosis in vogt-koyanagi-harada disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769357/ https://www.ncbi.nlm.nih.gov/pubmed/29334924 http://dx.doi.org/10.1186/s12886-018-0670-0 |
work_keys_str_mv | AT zhaochan longitudinalobservationofsubretinalfibrosisinvogtkoyanagiharadadisease AT dongfangtian longitudinalobservationofsubretinalfibrosisinvogtkoyanagiharadadisease AT gaofei longitudinalobservationofsubretinalfibrosisinvogtkoyanagiharadadisease AT liuxinshu longitudinalobservationofsubretinalfibrosisinvogtkoyanagiharadadisease AT peiminghang longitudinalobservationofsubretinalfibrosisinvogtkoyanagiharadadisease AT jiashanshan longitudinalobservationofsubretinalfibrosisinvogtkoyanagiharadadisease AT zhangmeifen longitudinalobservationofsubretinalfibrosisinvogtkoyanagiharadadisease |